Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Strategic Clinical Research Group, LLC
mi
from
Willow Park, TX
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Strategic Clinical Research Group, LLC
mi
from
Willow Park, TX
Click here to add this to my saved trials
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated:  12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
mi
from
Cherry Hill, NJ
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)
STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration
Status: Enrolling
Updated: 12/31/1969
Mid Atlantic Retina - Wills Eye Hospital
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Podocan and Wnt Pathway in the Development of Aortopathy in Bicuspid Valve Disease
Clinical Predictive Value of Podocan and Wnt Regulatory Molecules in Development of Aortopathy in Bicuspid Aortic Valve Disease
Status: Enrolling
Updated:  12/31/1969
Bassett Healthcare Network
mi
from
Cooperstown, NY
Podocan and Wnt Pathway in the Development of Aortopathy in Bicuspid Valve Disease
Clinical Predictive Value of Podocan and Wnt Regulatory Molecules in Development of Aortopathy in Bicuspid Aortic Valve Disease
Status: Enrolling
Updated: 12/31/1969
Bassett Healthcare Network
mi
from
Cooperstown, NY
Click here to add this to my saved trials
Alirocumab in Patients With Acute Myocardial Infarction
Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded Study
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Alirocumab in Patients With Acute Myocardial Infarction
Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded Study
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #3
mi
from
Beverly Hills, CA
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #3
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #4
mi
from
Murrieta, CA
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #4
mi
from
Murrieta, CA
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #5
mi
from
Oceanside, CA
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #5
mi
from
Oceanside, CA
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #3
mi
from
San Diego, CA
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #3
mi
from
San Diego, CA
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #5
mi
from
Clearwater, FL
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #5
mi
from
Clearwater, FL
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #5
mi
from
Coral Gables, FL
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #5
mi
from
Coral Gables, FL
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #7
mi
from
Palm Beach, FL
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #7
mi
from
Palm Beach, FL
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #16
mi
from
Washington, MO
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #16
mi
from
Washington, MO
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #9
mi
from
New York, NY
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #9
mi
from
New York, NY
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #19
mi
from
Nashville, TN
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #19
mi
from
Nashville, TN
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #24
mi
from
Pflugerville, TX
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #24
mi
from
Pflugerville, TX
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #26
mi
from
Charlottesville, VA
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #26
mi
from
Charlottesville, VA
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #25
mi
from
Lynchburg, VA
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #25
mi
from
Lynchburg, VA
Click here to add this to my saved trials
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated:  12/31/1969
Endo Clinical Trial Site #15
mi
from
Spokane, WA
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy
Status: Enrolling
Updated: 12/31/1969
Endo Clinical Trial Site #15
mi
from
Spokane, WA
Click here to add this to my saved trials
Initiation of CPAP for Newly Diagnosed OSA in Hospitalized Heart Failure Patients
Initiation of CPAP for Newly Diagnosed OSA in Hospitalized Heart Failure Patients: A Randomized Clinical Trial
Status: Enrolling
Updated:  12/31/1969
West Virginia University
mi
from
Morgantown, WV
Initiation of CPAP for Newly Diagnosed OSA in Hospitalized Heart Failure Patients
Initiation of CPAP for Newly Diagnosed OSA in Hospitalized Heart Failure Patients: A Randomized Clinical Trial
Status: Enrolling
Updated: 12/31/1969
West Virginia University
mi
from
Morgantown, WV
Click here to add this to my saved trials
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Status: Enrolling
Updated:  12/31/1969
Indiana University
mi
from
Indianapolis, IN
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Status: Enrolling
Updated: 12/31/1969
Indiana University
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Status: Enrolling
Updated:  12/31/1969
National Heart, Lung, and Blood Institute
mi
from
Bethesda, MD
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Status: Enrolling
Updated: 12/31/1969
National Heart, Lung, and Blood Institute
mi
from
Bethesda, MD
Click here to add this to my saved trials
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Status: Enrolling
Updated:  12/31/1969
University of British Columbia, Department of Medical Imaging
mi
from
Vancouver,
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017
Status: Enrolling
Updated: 12/31/1969
University of British Columbia, Department of Medical Imaging
mi
from
Vancouver,
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Midwest Institute for Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Icahn School of Medicine
mi
from
New York, NY
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Icahn School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Metabolic And Atherosclerosis Research Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Wellmont CVA Heart Institute
mi
from
Greeneville, TN
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Wellmont CVA Heart Institute
mi
from
Greeneville, TN
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
Amarillo Heart Clinical Research Institute Inc.
mi
from
Amarillo, TX
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
Amarillo Heart Clinical Research Institute Inc.
mi
from
Amarillo, TX
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
National Clinical Research, Inc.
mi
from
Richmond, VA
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
National Clinical Research, Inc.
mi
from
Richmond, VA
Click here to add this to my saved trials
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated:  12/31/1969
St. Paul's Hospital
mi
from
Vancouver,
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)
Status: Enrolling
Updated: 12/31/1969
St. Paul's Hospital
mi
from
Vancouver,
Click here to add this to my saved trials
Clinical Assessment Study in Crigler-Najjar Syndrome
LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome
Status: Enrolling
Updated:  12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Clinical Assessment Study in Crigler-Najjar Syndrome
LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome
Status: Enrolling
Updated: 12/31/1969
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Clinical Assessment Study in Crigler-Najjar Syndrome
LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome
Status: Enrolling
Updated:  12/31/1969
Clinic for Special Children
mi
from
Strasburg, PA
Clinical Assessment Study in Crigler-Najjar Syndrome
LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome
Status: Enrolling
Updated: 12/31/1969
Clinic for Special Children
mi
from
Strasburg, PA
Click here to add this to my saved trials
Clinical Assessment Study in Crigler-Najjar Syndrome
LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome
Status: Enrolling
Updated:  12/31/1969
Shaare Zedek Medical Center
mi
from
Jerusalem,
Clinical Assessment Study in Crigler-Najjar Syndrome
LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome
Status: Enrolling
Updated: 12/31/1969
Shaare Zedek Medical Center
mi
from
Jerusalem,
Click here to add this to my saved trials
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated:  12/31/1969
Heart Center Research, Llc
mi
from
Huntsville, AL
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated: 12/31/1969
Heart Center Research, Llc
mi
from
Huntsville, AL
Click here to add this to my saved trials
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated:  12/31/1969
Orlando Health
mi
from
Orlando, FL
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated: 12/31/1969
Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated:  12/31/1969
Allgemeines Krankenhaus Linz
mi
from
Linz,
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated: 12/31/1969
Allgemeines Krankenhaus Linz
mi
from
Linz,
Click here to add this to my saved trials
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated:  12/31/1969
Atlanta VA Medical Center
mi
from
Decatur, GA
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical Center
mi
from
Decatur, GA
Click here to add this to my saved trials
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated:  12/31/1969
Providence Everett Medical Center
mi
from
Everett, WA
PRESSUREwire Study
Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures
Status: Enrolling
Updated: 12/31/1969
Providence Everett Medical Center
mi
from
Everett, WA
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Athens Regional Medical Center
mi
from
Athens, GA
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Athens Regional Medical Center
mi
from
Athens, GA
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Medical Group
mi
from
Indianapolis, IN
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Medical Group
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Great Lakes Heart Center Of Alpena
mi
from
Alpena, MI
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Great Lakes Heart Center Of Alpena
mi
from
Alpena, MI
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
New York Methodist Hospital
mi
from
Brooklyn, NY
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
New York Methodist Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Univ. of Colorado at Denver and Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Holy Cross Hospital
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
University Hospital
mi
from
Augusta, GA
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
University Hospital
mi
from
Augusta, GA
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Tanner Medical Center
mi
from
Carrollton, GA
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Tanner Medical Center
mi
from
Carrollton, GA
Click here to add this to my saved trials
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated:  12/31/1969
Midwest Cardiovascular Research
mi
from
Elkhart, IN
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Status: Enrolling
Updated: 12/31/1969
Midwest Cardiovascular Research
mi
from
Elkhart, IN
Click here to add this to my saved trials